drugset / Trial / NCT06681415

Efficacy of 20% Human Albumin in Reducing Pleural Effusion After Cardiopulmonary Bypass

NCT06681415

RandomizedParallel-groupOpen-labelPrevention

Summary

Human albumin is a widely used additive in cardiopulmonary bypass all around the world, but its effect on various outcomes has been debated. The goal of this observational study is to compare the effect of 100 ml 20% human albumin addition to cardiopulmonary bypass on pleural effusion development after open heart surgery. The main question it aims to answer is: • Does albumin, in addition to cardiopulmonary bypass, reduce pleural effusion development after open heart surgery? Patients will go under elective open heart surgery. Investigators will compare pleural effusion volume on the first day after surgery between patients who received albumin and those who didn't.

Timeline

Start
2022-09-01
Primary completion
2023-12-01
Completion
2024-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 100 ml

Indications

No indication recorded.